Extrapolation of PK Bioequivalence to an Alternative Comparator due to RLD/RS UnavailabilityOctober 7, 2025October 7, 2025Back to: Advancing Generic Drug Development 2025 Previous LessonUpdates and Current Landscape for Study Population Selection and Additional Mitigation Strategies in Bioequivalence StudiesLesson 4 within section Session 2: Novel Bioequivalence Study Design Recommendations. Next LessonSession 2: Q&A Panel and Day 1 Closing (Advancing Generic Drug Development 2025)Lesson 6 within section Session 2: Novel Bioequivalence Study Design Recommendations. You must enroll in this course to access course content. Presenter Yuqing Gong, PhDSenior PharmacologistDQMM | ORS | OGD | CDER | FDA Leave a Comment Cancel replyLogin with your Social IDYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment. Δ